跳至主要内容
临床试验/JPRN-jRCTs041200072
JPRN-jRCTs041200072进行中(未招募)2 期

COVID-19 Prevention of worsening of symptoms in asymptomatic to mild patients by combined use of kakkonto and hochuekkito:Exploratory open-label randomized controlled trial - HKCOV

Ogawa Keiko0 个研究点目标入组 100 人开始时间: 2020年12月10日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1) SARS-CoV-2 is positive in nucleic acid detection or antigen test.
  • 2) 20years old or over
  • 3) Asymptomatic or mild symptoms.

排除标准

  • 1) Administration of kampo medicine (Juzendaihoto,Ninjinyoueito, Hochuekkito, Seishoekkito, Rikkunshito, Shikunshito, Kihito, Kamikihito) within the last two weeks
  • 2) Persons with a history of hypersensitivity to Hochuekkito or Kakkonto
  • 3) Those who participated in other clinical intervention studies (studies) within 3 months before the start of study drug administration
  • 4) A person who is judged by the principal investigator or the investigator to be inappropriate as a research subject.
  • 5) Those who are pregnant, may be pregnant, or are breastfeeding

研究者

发起方
Ogawa Keiko

相似试验